NO20021907L - Metoder og blandinger som anvender kinazolinoner - Google Patents

Metoder og blandinger som anvender kinazolinoner

Info

Publication number
NO20021907L
NO20021907L NO20021907A NO20021907A NO20021907L NO 20021907 L NO20021907 L NO 20021907L NO 20021907 A NO20021907 A NO 20021907A NO 20021907 A NO20021907 A NO 20021907A NO 20021907 L NO20021907 L NO 20021907L
Authority
NO
Norway
Prior art keywords
quinazolinones
mixtures
methods
formulae
useful
Prior art date
Application number
NO20021907A
Other languages
English (en)
Other versions
NO20021907D0 (no
NO322825B1 (no
Inventor
Jeffrey T Finer
Gustave Bergnes
Bainian Feng
Whitney W Smith
John C Chabala
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of NO20021907D0 publication Critical patent/NO20021907D0/no
Publication of NO20021907L publication Critical patent/NO20021907L/no
Publication of NO322825B1 publication Critical patent/NO322825B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)
NO20021907A 1999-10-27 2002-04-23 Kinazolinoner, syntese av slike, anvendelse av slike for fremstilling av medikamenter for behandling av proliferative sykdommer, farmasoytiske preparater inneholdende slike forbindelser samt anvendelse in vitro for a hemme KSP-kinase. NO322825B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19825399P 1999-10-27 1999-10-27
US21310400P 2000-06-21 2000-06-21
PCT/US2000/029585 WO2001030768A1 (en) 1999-10-27 2000-10-26 Methods and compositions utilizing quinazolinones

Publications (3)

Publication Number Publication Date
NO20021907D0 NO20021907D0 (no) 2002-04-23
NO20021907L true NO20021907L (no) 2002-06-07
NO322825B1 NO322825B1 (no) 2006-12-11

Family

ID=26893612

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021907A NO322825B1 (no) 1999-10-27 2002-04-23 Kinazolinoner, syntese av slike, anvendelse av slike for fremstilling av medikamenter for behandling av proliferative sykdommer, farmasoytiske preparater inneholdende slike forbindelser samt anvendelse in vitro for a hemme KSP-kinase.

Country Status (19)

Country Link
EP (2) EP1226129B1 (no)
JP (2) JP2003512461A (no)
KR (2) KR20050049562A (no)
CN (1) CN100381428C (no)
AT (1) ATE327224T1 (no)
AU (2) AU774748B2 (no)
BR (1) BR0015110A (no)
CA (1) CA2388646C (no)
CZ (1) CZ20021428A3 (no)
DE (1) DE60028227T2 (no)
ES (1) ES2263501T3 (no)
HK (1) HK1045994A1 (no)
HU (1) HUP0203430A3 (no)
IL (2) IL149164A0 (no)
MX (1) MXPA02004162A (no)
NO (1) NO322825B1 (no)
NZ (2) NZ518480A (no)
PL (1) PL203998B1 (no)
WO (1) WO2001030768A1 (no)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342257T1 (de) 1999-08-27 2006-11-15 Chemocentryx Inc Heterozyclische verbindungen und verfahren zur modulierung von cxcr3 funktion
US20070021493A1 (en) 1999-09-16 2007-01-25 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7115653B2 (en) 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US8852937B2 (en) 2000-03-30 2014-10-07 Curis, Inc. Small organic molecule regulators of cell proliferation
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2002083143A1 (en) 2000-12-11 2002-10-24 Tularik Inc. Cxcr3 antagonists
US6992082B2 (en) 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
CZ20033457A3 (cs) 2001-06-22 2004-09-15 Pfizer Products Inc. Farmaceutická kompozice zahrnující léčiva s nízkou rozpustností a/nebo léčiva citlivá na kyselinu a neutralizované kyselé polymery
DE60236605D1 (de) 2001-09-05 2010-07-15 Minerva Biotechnologies Corp Zusammensetzungen und deren verwendung zur behandlung von krebs
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043961A2 (en) * 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
WO2003050122A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE447577T1 (de) 2001-12-06 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
DE60232994D1 (de) 2001-12-06 2009-08-27 Merck & Co Inc Inhibitoren von mitotischem kinesin
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
WO2003050064A2 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2469801C (en) 2001-12-11 2011-06-21 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
RU2004135554A (ru) * 2002-05-09 2006-01-20 Цитокинетикс, Инк. (Us) Пиримидиноны, композиции на их основе и способы их использования
US7301028B2 (en) * 2002-06-14 2007-11-27 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2004006865A2 (en) * 2002-07-17 2004-01-22 Cytokinetics, Inc. Compounds, compositions, and methods
US7208487B2 (en) * 2002-12-13 2007-04-24 Cytokinetics, Incorporated Compounds, compositions and methods
EP1608317B1 (en) * 2003-03-25 2012-09-26 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004092123A2 (en) * 2003-04-10 2004-10-28 Microbia, Inc. Inhibitors of fungal invasion
CA2522594C (en) 2003-04-18 2012-01-24 Kyowa Hakko Kogyo Co., Ltd. Mitotic kinesin inhibitor
AU2004249730A1 (en) 2003-06-20 2004-12-29 Novartis Vaccines And Diagnostics, Inc. Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents
JP2007502773A (ja) * 2003-08-15 2007-02-15 メルク　エンド　カムパニー　インコーポレーテッド 有糸***キネシン阻害薬
KR20060127413A (ko) 2003-11-25 2006-12-12 카이론 코포레이션 항암제로서의 퀴나졸리논 화합물
US7439254B2 (en) * 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
US7662581B1 (en) 2003-12-18 2010-02-16 Novartis Vaccines And Diagnostics, Inc. Eg5 co-crystals
AU2004305069C1 (en) 2003-12-19 2010-07-29 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2005061707A1 (ja) * 2003-12-24 2005-07-07 Kyowa Hakko Kogyo Co., Ltd. 癌細胞のEg5阻害剤に対する感受性を判定する方法
CA2560213A1 (en) * 2004-03-22 2005-10-06 Merck & Co., Inc. Mitotic kinesin inhibitors
ES2425476T3 (es) 2004-04-02 2013-10-15 Prana Biotechnology Limited Compuestos neurológicamente activos
CN101031569B (zh) 2004-05-13 2011-06-22 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
CA2564215A1 (en) 2004-05-21 2005-12-01 Chiron Corporation Substituted quinoline derivatives as mitotic kinesin inhibitors
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
AU2005258135B2 (en) 2004-06-18 2011-09-22 Novartis Vaccines And Diagnostics Inc. N- (1- (1-benzyl -4-phenyl-1H-imidazol-2-YL) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
US7939538B2 (en) 2004-06-28 2011-05-10 Amgen Inc. Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
MX2007001953A (es) 2004-08-18 2007-05-09 Astrazeneca Ab Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
JP5635726B2 (ja) * 2004-09-14 2014-12-03 ミネルバ バイオテクノロジーズ コーポレーション 癌の診断方法及び治療方法
AU2005301133A1 (en) 2004-10-19 2006-05-11 Novartis Vaccines And Diagnostics Inc. Indole and benzimidazole derivatives
JP4545196B2 (ja) * 2005-01-19 2010-09-15 メルク・シャープ・エンド・ドーム・コーポレイション 有糸***キネシン阻害剤
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
EP1908755A4 (en) 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd THERAPEUTIC AGENT AGAINST RESTENOSIS
MY147188A (en) * 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
WO2008057468A1 (en) 2006-11-02 2008-05-15 Curis, Inc. Small organic molecule regulators of cell proliferation
US8129358B2 (en) 2006-11-13 2012-03-06 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
NZ577727A (en) 2007-01-05 2012-03-30 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
KR101591656B1 (ko) 2007-01-10 2016-02-19 엠에스디 이탈리아 에스.알.엘. 폴리(ａｄｐ-리보오스) 폴리머라아제(ｐａｒｐ) 억제제로서의 아미드 치환된 인다졸
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
EP2152700B1 (en) 2007-05-21 2013-12-11 Novartis AG Csf-1r inhibitors, compositions, and methods of use
US8232285B2 (en) 2007-06-22 2012-07-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
NZ592880A (en) 2008-11-13 2013-06-28 Gilead Calistoga Llc Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy
EA201270184A1 (ru) 2009-07-21 2012-08-30 ГИЛИЭД КАЛИСТОГА ЭлЭлСи Лечение расстройств печени ингибиторами pi3k
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
MD20140100A2 (ro) 2012-03-05 2015-01-31 Gilead Calistoga Llc Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
NZ708870A (en) 2012-12-21 2016-09-30 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
ES2677919T3 (es) 2012-12-21 2018-08-07 Gilead Calistoga Llc Aminoalquil-quinazolonas sustituidas con pirimidina como inhibidores de la fosfatidilinositol 3-quinasa
TWI644909B (zh) 2013-06-14 2018-12-21 基利科學股份有限公司 磷脂酸肌醇３－激酶抑制劑
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2934534A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
JP2017502021A (ja) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤のためのプロセス方法
EP3154969B1 (en) 2014-06-13 2019-10-09 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
BR112016028876A2 (pt) 2014-06-13 2017-08-22 Gilead Sciences Inc composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
JP6454736B2 (ja) 2014-06-13 2019-01-16 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
KR20170012560A (ko) 2014-06-13 2017-02-02 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
CN111189935A (zh) * 2019-12-30 2020-05-22 卓和药业集团有限公司 盐酸右美托咪定的高效液相色谱分析方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
ES2245015T3 (es) * 1997-06-09 2005-12-16 Pfizer Products Inc. Quinazolin-4-onas como antagonistas de ampa.
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones

Also Published As

Publication number Publication date
IL149164A0 (en) 2002-11-10
WO2001030768A1 (en) 2001-05-03
CN100381428C (zh) 2008-04-16
ATE327224T1 (de) 2006-06-15
BR0015110A (pt) 2002-07-02
CA2388646C (en) 2009-01-27
EP1226129A1 (en) 2002-07-31
MXPA02004162A (es) 2003-08-20
HUP0203430A3 (en) 2003-07-28
KR20020062930A (ko) 2002-07-31
EP1686120A2 (en) 2006-08-02
AU1439801A (en) 2001-05-08
NZ530074A (en) 2005-03-24
AU774748B2 (en) 2004-07-08
EP1686120A3 (en) 2007-05-30
HUP0203430A2 (en) 2003-05-28
HK1045994A1 (en) 2002-12-20
IL149164A (en) 2007-05-15
PL354891A1 (en) 2004-03-22
EP1226129B1 (en) 2006-05-24
CN1413198A (zh) 2003-04-23
DE60028227T2 (de) 2007-03-29
AU2004218601A1 (en) 2004-10-28
WO2001030768A9 (en) 2002-08-15
DE60028227D1 (de) 2006-06-29
ES2263501T3 (es) 2006-12-16
PL203998B1 (pl) 2009-11-30
NZ518480A (en) 2004-02-27
KR20050049562A (ko) 2005-05-25
JP2003512461A (ja) 2003-04-02
CZ20021428A3 (cs) 2002-11-13
CA2388646A1 (en) 2001-05-03
JP2003048881A (ja) 2003-02-21
NO20021907D0 (no) 2002-04-23
NO322825B1 (no) 2006-12-11
JP4116332B2 (ja) 2008-07-09

Similar Documents

Publication Publication Date Title
NO20021907L (no) Metoder og blandinger som anvender kinazolinoner
DK1296959T3 (da) Fremgangsmåder og præparater med anvendelse af quinazolinoner
WO2003103575A3 (en) COMPOUNDS, COMPOSITIONS AND METHODS
SE9900100D0 (sv) New compounds
WO2004018058A3 (en) Compounds, compositions, and methods
MY140767A (en) Compounds, methods and compositions
NO20052267L (no) Forbindelser, Preparater og Metoder
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
WO2003088903A3 (en) Compounds, compositions, and methods
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
WO2004009036A3 (en) Compounds compositions and methods
AU2003252025A8 (en) Compounds, compositions, and methods
WO2004034972A3 (en) Compounds, compositions, and methods
WO2004064741A3 (en) Compounds, compositions, and methods
WO2005046588A3 (en) Compounds, compositions, and methods
WO2005042697A3 (en) Compounds, compositions and methods
WO2004032879A3 (en) Compounds, compositions, and methods
WO2005062847A3 (en) Compounds, compositions and methods
WO2005060692A3 (en) Biphenyl compounds and methods
ECSP993064A (es) Compuestos organicos
UA51556A (uk) Спосіб лікування хворих на уросепсис

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees